Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

930 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.
Squires K, Bekker LG, Katlama C, Yazdanpanah Y, Zhou Y, Rodgers AJ, DiNubile MJ, Sklar PA, Leavitt RY, Teppler H. Squires K, et al. Among authors: katlama c. Open Forum Infect Dis. 2017 Feb 28;4(1):ofw047. doi: 10.1093/ofid/ofw047. eCollection 2017 Winter. Open Forum Infect Dis. 2017. PMID: 28480227 Free PMC article.
[The Nadis cohort: 6236 HIV-infected patients followed up in French university hospitals].
Agher R, Duvivier C, Katlama C, Gérard Y, Yazdanpanah Y, Billaud E, Jovelin T, Raffi F, Enel P, Poizot-Martin I, Puglièse P, Dellamonica P, Barone M, Cuzin L, Marchou B; Groupe Nadis. Agher R, et al. Among authors: katlama c. Med Mal Infect. 2005 Jul-Aug;35(7-8):407-10. doi: 10.1016/j.medmal.2005.06.004. Med Mal Infect. 2005. PMID: 16139459 French.
Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. Steigbigel RT, et al. Among authors: katlama c. N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975. N Engl J Med. 2008. PMID: 18650512 Free article. Clinical Trial.
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Cooper DA, et al. Among authors: katlama c. N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978. N Engl J Med. 2008. PMID: 18650513 Free article. Clinical Trial.
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 study group. De Castro N, et al. Among authors: katlama c. Clin Infect Dis. 2009 Oct 15;49(8):1259-67. doi: 10.1086/605674. Clin Infect Dis. 2009. PMID: 19757993 Clinical Trial.
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group. Yazdanpanah Y, et al. Among authors: katlama c. Clin Infect Dis. 2009 Nov 1;49(9):1441-9. doi: 10.1086/630210. Clin Infect Dis. 2009. PMID: 19814627 Clinical Trial.
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Steigbigel RT, et al. Among authors: katlama c. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002. Clin Infect Dis. 2010. PMID: 20085491 Free PMC article. Clinical Trial.
Risk factors of chronic kidney disease in HIV-infected patients.
Flandre P, Pugliese P, Cuzin L, Bagnis CI, Tack I, Cabié A, Poizot-Martin I, Katlama C, Brunet-François C, Yazdanpanah Y, Dellamonica P; New AIDS Data group. Flandre P, et al. Among authors: katlama c. Clin J Am Soc Nephrol. 2011 Jul;6(7):1700-7. doi: 10.2215/CJN.09191010. Epub 2011 May 12. Clin J Am Soc Nephrol. 2011. PMID: 21566114
930 results